Support teaching, research, and patient care.
Diana V. Do, MD, is Professor of Ophthalmology and Vice Chair for Clinical Affairs at the Byers Eye Institute, Stanford University. In addition, she is Clinic Chief of Ophthalmology at Stanford Health Care.She is an internationally recognized physician who specializes in the surgical and medical treatment of retinal disorders. Dr. Do is a board-certified ophthalmologist and is an expert in the management of age related macular degeneration, diabetic retinopathy, vein occlusion, retinal detachment, macular hole, infections, cataract, and epiretinal membrane. She incorporates state-of-the-art treatment options for her patients while treating each individual with compassion and dignity. Her goal is to provide the highest level of care for each patient. She has been selected as a "Top Doctor" in the Bay Area, and she has been voted as one of the "100 Top Women in Ophthalmology" in the Ophthalmologist Power List.Dr. Do is a leading surgeon-scientist who has authored over 150 publications in the medical literature and has contributed to over 25 book chapters. She has been the principal investigator and co-investigator on more than 45 clinical trials investigating novel treatments for retinal diseases and ocular inflammation. She has over 15 years of experience in leading clinical trials for retinal and ocular diseases. She has been an invited lecturer throughout the North and South America, Europe, and Asia. Furthermore, she has directed and participated in many continuing medical education courses for ophthalmologists and retina specialists throughout the United States and abroad.Before joining Stanford, Dr. Do was Associate Professor of Ophthalmology at the Wilmer Eye Institute, the Johns Hopkins University School of Medicine in Baltimore, Maryland. At Hopkins, she was Head of the Retina Fellowship Training Program and she conducted cutting edge research to develop more effective therapies for diabetic retinopathy and age-related macular degeneration. After her tenure at Johns Hopkins, she was recruited to serve as Vice Chair of Education and Professor of Ophthalmology at the University of Nebraska College of Medicine. In addition, she was Program Director of the ophthalmology residency training program and Director of the Retinal Fellowship Training Program at Nebraska.Dr. Do was educated at the University of California at Berkeley where she graduated summa cum laude with a Bachelor of Arts in Molecular and Cellular Biology. She received her medical degree (Alpha Omega Alpha) and was a Regents Scholar at the University of California San Francisco School of Medicine. After completing her medicine internship at Massachusetts General Hospital / Harvard Medical School, she pursued both her ophthalmology training and retina fellowship at the Wilmer Eye Institute, the Johns Hopkins University School of Medicine. Her academic achievements have been recognized with numerous national awards including the Heed Ophthalmic Foundation Clinician-Scientist Award, the Ronald Michels Fellowship Foundation Award, the Honor Award from the American Society of Retina Specialists, and the Achievement Award from the American Academy of Ophthalmology. Dr. Do serves as Vice Chair for Clinical Affairs for the Ophthalmology Department and Clinic Chief. In addition, she is the Physician Improvement Leader for Quality Improvement (QI) and collaborates on numerous QI projects with faculty to improve patient experience, quality, and access to outstanding eye care at the Byers Eye Institute. She has an active clinical and surgical practice while she continues to investigate novel treatments for retinal diseases. She teaches medical students, residents, and retina fellows at Stanford, and she is a member of the Education Committee. Her outstanding teaching skills have been recognized with the Faculty Teaching Award, which is given annually to the most outstanding faculty member who contributes to resident education.
Dr. Do's research focuses on collaborative clinical trials to investigate novel treatments for retinal vascular diseases and ocular inflammation. She is an internationally recognized clinician scientist who has been the principal investigator on numerous clinical trials in retinal vascular diseases. She performs research to develop state of the art therapies for age-related macular degeneration, diabetic eye disease, retinal vein occlusion, retinal inflammation, and retinal detachment.
Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITE III)
This LIGHTSITE III study is a double-masked, sham-controlled, parallel design, prospective
multi-site study for the use of PBM as a treatment for visual impairment in subjects with dry
Stanford is currently not accepting patients for this trial.
For more information, please contact SPECTRUM, .
View full details
Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease
The primary objective of the study is to determine if treatment with high-dose aflibercept
(HD) at intervals of 12 or 16 weeks provides non-inferior best corrected visual acuity (BCVA)
compared to aflibercept dosed every 8 weeks.
The secondary objectives of the study are as follows:
- To determine the effect of HD vs. aflibercept on anatomic and other visual measures of
- To evaluate the safety, immunogenicity, and pharmacokinetics (PK) of aflibercept
A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor)
The objectives of this study are to evaluate the safety and efficacy of Zimura (avacincaptad
pegol) intravitreal administration in patients with geographic atrophy secondary to
age-related macular degeneration (AMD)
LUMINA Phase III Study Assessing the Efficacy and Safety of Intravitreal Injections of 440 ug DE-109 Sirolimus for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye
This is a Phase III study to assess the efficacy and safety of DE-109 440 µg every 2 months
in subjects with active, non-infectious uveitis of the posterior segment of the eye (NIU-PS).
There is a 6-month, single-arm, open-label period after completion of the 6-month double-
masked, controlled period allows the evaluation of the efficacy and safety of intravitreal
injection of DE-109 440 µg every 2 months for longer duration than appropriate for a placebo
or sham control.